Delcath Systems (DCTH) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Delcath Systems (DCTH) has outperformed MaxCyte (MXCT) over the past year, gaining 35.5% versus a loss of 32.9%. Over five years, DCTH leads with a +59.8% price change compared with -90.6% for MXCT. Delcath Systems is the larger company by market cap ($521.9 million vs $105.3 million), about 5.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | MXCT |
|---|---|---|
| Share price | $15.04 | $1.02 |
| Market cap | $521.87M | $105.27M |
| 1-day change | -2.21% | -1.92% |
| YTD return | +48.91% | -32.90% |
| 1-year return | +35.50% | -32.90% |
| 5-year return | +59.83% | -90.57% |
| Forward P/E | 334.22 | — |
| EPS (TTM) | $0.01 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $1.87 |
| 52-week low | $8.12 | $0.643 |
| Distance from 52-week high | -13.66% | -45.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +59.57% | +302.94% |
| Average volume | 479.73K | 668.82K |
| Shares outstanding | 34.70M | 103.21M |
| Employees | 156 | 91 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Delcath Systems is about 5.0 times larger than MaxCyte by market value ($521.87M vs $105.27M).
- DCTH has outperformed MXCT by 68.4 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Healthcare · Medical Devices · 156 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
DCTH vs MXCT FAQ
Which is bigger, Delcath Systems or MaxCyte?
Delcath Systems (DCTH) is larger, with a market capitalization of $521.87M compared with $105.27M for MaxCyte (MXCT).
Which stock has performed better over the past year, DCTH or MXCT?
DCTH returned +35.50% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and MaxCyte in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.